James Harris

Dr. James Harris

Department of Medicine, School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing & Health Sciences, Monash University, Monash Medical Centre, Clayton, Victoria 3800, Australia

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2010 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
SMSeth L Masters
Seth L Masters
ADAisling Dunne
Aisling Dunne
SSShoba L Subramanian
Shoba L Subramanian
RHRebecca L Hull
Rebecca L Hull
GTGillian M Tannahill
Gillian M Tannahill
Luke O'NeillLuke O'Neill
Luke O'Neill

1 March 2011 in Journal of Biological Chemistry
Verified
Journal Article
Open access
James HarrisJames Harris
James Harris
MHMichelle Hartman
Michelle Hartman
CRCaitrionna Roche
Caitrionna Roche
SZShijuan G. Zeng
Shijuan G. Zeng
AOAmy O'SHea
Amy O'SHea
ELEd C. Lavelle
Ed C. Lavelle
Autophagy is a key regulator of cellular homeostasis that can be activated by pathogen-associated molecules and recently has been shown to influence IL-1β secretion by macrophages. However, the mechanisms behind this are unclear. Here, we describe a novel role for autophagy in regulating the production of IL-1β in antigen-presenting cells. After treatment of macrophages with Toll-like receptor ligands, pro-IL-1β was specifically sequestered into autophagosomes, whereas further activation of autophagy with rapamycin induced the degradation of pro-IL-1β and blocked secretion of the mature cytokine. Inhibition of autophagy promoted the processing and secretion of IL-1β by antigen-presenting cells in an NLRP3- and TRIF-dependent manner. This effect was reduced by inhibition of reactive oxygen species but was independent of NOX2. Induction of autophagy in mice in vivo with rapamycin reduced serum levels of IL-1β in response to challenge with LPS. These data demonstrate that autophagy controls the production of IL-1β through at least two separate mechanisms: by targeting pro-IL-1β for lysosomal degradation and by regulating activation of the NLRP3 inflammasome.

20 January 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
FSFiona A. Sharp
Fiona A. Sharp
DRDarren Ruane
Darren Ruane
BCBenjamin Claass
Benjamin Claass
ECEmma Creagh
Emma Creagh
James HarrisJames Harris
James Harris
ELEdward Lavelle
Edward Lavelle
Many currently used and candidate vaccine adjuvants are particulate in nature, but their mechanism of action is not well understood. Here, we show that particulate adjuvants, including biodegradable poly(lactide- co -glycolide) (PLG) and polystyrene microparticles, dramatically enhance secretion of interleukin-1β (IL-1β) by dendritic cells (DCs). The ability of particulates to promote IL-1β secretion and caspase 1 activation required particle uptake by DCs and NALP3. Uptake of microparticles induced lysosomal damage, whereas particle-mediated enhancement of IL-1β secretion required phagosomal acidification and the lysosomal cysteine protease cathepsin B, suggesting a role for lysosomal damage in inflammasome activation. Although the presence of a Toll-like receptor (TLR) agonist was required to induce IL-1β production in vitro, injection of the adjuvants in the absence of TLR agonists induced IL-1β production at the injection site, indicating that endogenous factors can synergize with particulates to promote inflammasome activation. The enhancement of antigen-specific antibody production by PLG microparticles was independent of NALP3. However, the ability of PLG microparticles to promote antigen-specific IL-6 production by T cells and the recruitment and activation of a population of CD11b + Gr1 − cells required NALP3. Our data demonstrate that uptake of microparticulate adjuvants by DCs activates the NALP3 inflammasome, and this contributes to their enhancing effects on innate and antigen-specific cellular immunity.

1 September 2007 in Immunity
Verified
Journal Article
Closed access
James HarrisJames Harris
James Harris
SHSergio A. De Haro
Sergio A. De Haro
SMSharon S. Master
Sharon S. Master
JKJoseph Keane
Joseph Keane
EREsteban A. Roberts
Esteban A. Roberts
VDVojo Deretic
Vojo Deretic

1 November 2011 in Cytokine
Verified
Journal Article
Closed access
James HarrisJames Harris
James Harris

1 May 2006 in Cellular Microbiology
Verified
Journal Article
Closed access
PDF file
VDVojo Deretic
Vojo Deretic
SSSudha Singh
Sudha Singh
SMSharon Master
Sharon Master
James HarrisJames Harris
James Harris
EREsteban Roberts
Esteban Roberts
IVIsabelle VERGNE
Isabelle VERGNE
A marquee feature of the powerful human pathogen Mycobacterium tuberculosis is its macrophage parasitism. The intracellular survival of this microorganism rests upon its ability to arrest phagolysosome biogenesis, avoid direct cidal mechanisms in macrophages, and block efficient antigen processing and presentation. Mycobacteria prevent Rab conversion on their phagosomes and elaborate glycolipid and protein trafficking toxins that interfere with Rab effectors and regulation of specific organellar biogenesis in mammalian cells. One of the major Rab effectors affected in this process is the type III phosphatidylinositol 3-kinase hVPS34 and its enzymatic product phosphatidylinositol 3-phosphate (PI3P), a regulatory lipid earmarking organellar membranes for specific trafficking events. PI3P is also critical for the process of autophagy, recently recognized as an effector of innate and adaptive immunity. Induction of autophagy by physiological, pharmacological or immunological signals, including the major antituberculosis Th1 cytokine IFN-gamma and its downstream effector p47 GTPase LRG-47, can overcome mycobacterial phagosome maturation block and inhibit intracellular M. tuberculosis survival. This review summarizes the findings centred around the PI3P-nexus where the mycobacterial phagosome maturation block and execution stages of autophagy intersect.